Shares of Vertex Pharmaceuticals (VRTX) surged more than 42% Tuesday on volume that is already 11 times above the daily average after the company said two Phase III trials for its cystic fibrosis ...

(Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 ...

On Tuesday, RBC Capital Markets adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), raising it to $420 from the previous $408, while maintaining a Sector Perform rating ...

(Reuters) - An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio to as much as $2.05 ...

US manufacturer Lift-A-Loft has unveiled a new compact vertical mast lift, called Vertex. Vertex can elevate to 12 ft (3.6 m) of platform height allowing a working height of 18 ft (5.5 m). The compact ...

to a class of medicines called nucleotide analogues, or nucs. “It’s all due to the data on their nuc,” Brean Murray, Carret & Co analyst Brian Skorney said of the Vertex share jump. He said the data ...

Shares of biotechnology firm Vertex Pharmaceuticals (NASDAQ:VRTX) are soaring by more than 55 percent early Friday and have touched a new all-time high after the company announced late Thursday that ...